Based on 5 Wall Street analysts offering 12 month price targets for Mirati Therapeutics in the last 3 months. The average price target is €53.94 with a high forecast of €54.24 and a low forecast of €53.32. The average price target represents a 1.19% change from the last price of €53.30.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"plus_tr_sans","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"25":"€25","42":"€42","59":"€59","33.5":"€33.5","50.5":"€50.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":54.239585,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n  <span style=\"color:#199ca5\">€54.24</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":53.93621105,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n  <span style=\"color:#828080\">€53.94</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":53.32027,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n  <span style=\"color:#912767\">€53.32</span>\n  </div></div>","useHTML":true}}],"tickPositions":[25,33.5,42,50.5,59],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Apr<br/>2023","6":"Jul<br/>2023","9":"Oct<br/>2023","12":"Jan<br/>2024","25":"Jan<br/>2025"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,53.22,53.29842961538461,53.37685923076923,53.45528884615384,53.53371846153846,53.61214807692308,53.69057769230769,53.769007307692306,53.84743692307692,53.925866538461534,54.004296153846155,54.08272576923077,54.161155384615384,{"y":54.239585,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,53.22,53.275093157692304,53.330186315384616,53.38527947307692,53.44037263076923,53.49546578846154,53.55055894615384,53.605652103846154,53.66074526153846,53.715838419230764,53.770931576923076,53.82602473461538,53.88111789230769,{"y":53.93621105,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,53.22,53.227713076923074,53.235426153846156,53.24313923076923,53.250852307692305,53.25856538461539,53.26627846153846,53.27399153846154,53.28170461538461,53.289417692307694,53.29713076923077,53.304843846153844,53.312556923076926,{"y":53.32027,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":39.6,"date":1674172800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":49.2,"date":1675382400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":41.8,"date":1677801600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33.6,"date":1680825600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":40.33,"date":1683244800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33.99,"date":1685664000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":35.84,"date":1688688000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.87,"date":1691107200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33.95,"date":1693526400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":58.58,"date":1696550400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":51.94,"date":1698969600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":51.42,"date":1701388800000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":53.22,"date":1704412800000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target€54.24

Average Price Target€53.94

Lowest Price Target€53.32

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

xxxxxxxxxxxxxxxxxx

Scotiabank

xxxxxxxxxxxxx

Reiterated

01/24/24

xxxxxxxxxxxxxxxxxx

Citi

xxxxxxxxxxxxx

Downgraded

12/19/23

xxxxxxxxxxxxxxxxxx

JMP Securities

xxxxxxxxxxxxx

Reiterated

11/07/23

xxxxxxxxxxxxxxxxxx

Leerink Partners

xxxxxxxxxxxxx

Downgraded

11/07/23

xxxxxxxxxxxxxxxxxx

Stifel Nicolaus

xxxxxxxxxxxxx

Downgraded

11/06/23

xxxxxxxxxxxxxxxxxx

JonesTrading

xxxxxxxxxxxxx

Assigned

10/20/23

xxxxxxxxxxxxxxxxxx

Piper Sandler

xxxxxxxxxxxxx

Downgraded

10/10/23

xxxxxxxxxxxxxxxxxx

TD Cowen

xxxxxxxxxxxxx

Downgraded

10/10/23

xxxxxxxxxxxxxxxxxx

J.P. Morgan

xxxxxxxxxxxxx

Reiterated

10/09/23

xxxxxxxxxxxxxxxxxx

B.Riley Financial

xxxxxxxxxxxxx

Downgraded

10/09/23

Maury Raycroft

Jefferies

€53.32

Hold

0.04%

Upside

Downgraded

10/08/23

Mirati Therapeutics (MRTX) downgraded to Hold from Buy at Jefferies

Jay Olson

Oppenheimer

€57.00

Buy

6.94%

Upside

Reiterated

10/06/23

Oppenheimer Remains a Buy on Mirati Therapeutics (MRTX)

Evan Seigerman

BMO Capital

€66.19

Hold

24.19%

Upside

Assigned

10/05/23

Hold Rating for Mirati Amid Potential Sanofi Takeout and Lumakras Adcom Decision: A Revised Financial Outlook

Gena Wang

Barclays

€65.27

Buy

22.46%

Upside

Reiterated

08/09/23

Mirati Therapeutics (MRTX) Has a New Rating from Barclays

Michael Ulz

Morgan Stanley

€34.01

Hold

-36.18%

Downside

Reiterated

08/09/23

Mirati Therapeutics (MRTX) PT Lowered to $37 at Morgan StanleyMorgan Stanley analyst Michael Ulz lowered the price target on Mirati Therapeutics (NASDAQ: MRTX) to $37.00 (from $42.00) while maintaining a Equalweight rating.

Best Analysts Covering Mirati Therapeutics

Which Analyst Should I Follow If I Want to Buy DE:26M and Sell After:

1 Month

Jay OlsonOppenheimer

Success Rate

9/17 ratings generated profit

Average Return

+4.41%

reiterated a buy rating 7 months ago

Copying Jay Olson's trades and holding each position for 1 Month would result in 52.94% of your transactions generating a profit, with an average return of +4.41% per trade.

dummydummy

Success Rate

0/0 ratings generated profit

Average Return

0.00%

a rating ―

Copying dummy's trades and holding each position for XXXX would result in 0.10% of your transactions generating a profit, with an average return of 0.00% per trade.

Premium Content

Find out which analyst has the highest Average Return & Success Rate

Go Premium

3 Months

Jay OlsonOppenheimer

Success Rate

11/17 ratings generated profit

Average Return

+17.84%

reiterated a buy rating 7 months ago

Copying Jay Olson's trades and holding each position for 3 Months would result in 64.71% of your transactions generating a profit, with an average return of +17.84% per trade.

dummydummy

Success Rate

0/0 ratings generated profit

Average Return

0.00%

a rating ―

Copying dummy's trades and holding each position for XXXX would result in 0.10% of your transactions generating a profit, with an average return of 0.00% per trade.

Premium Content

Find out which analyst has the highest Average Return & Success Rate

Go Premium

1 Year

Jay OlsonOppenheimer

Success Rate

12/17 ratings generated profit

Average Return

+40.28%

reiterated a buy rating 7 months ago

Copying Jay Olson's trades and holding each position for 1 Year would result in 70.59% of your transactions generating a profit, with an average return of +40.28% per trade.

2 Years

Jay OlsonOppenheimer

Success Rate

12/17 ratings generated profit

Average Return

+40.60%

reiterated a buy rating 7 months ago

Copying Jay Olson's trades and holding each position for 2 Years would result in 70.59% of your transactions generating a profit, with an average return of +40.60% per trade.

dummydummy

Success Rate

0/0 ratings generated profit

Average Return

0.00%

a rating ―

Copying dummy's trades and holding each position for XXXX would result in 0.10% of your transactions generating a profit, with an average return of 0.00% per trade.

Premium Content

Find out which analyst has the highest Average Return & Success Rate

Go Premium

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

26M Analyst Recommendation Trends

Rating

Aug 23

Sep 23

Oct 23

Nov 23

Dec 23

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, 26M has received 8 Buy Ratings, 13 Hold Ratings, and 1 Sell Ratings. 26M average Analyst price target in the past 3 months is €53.94.

Each month's total comprises the sum of three months' worth of ratings.

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxxxxxxxxxxxxxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

26M Financial Forecast

26M Earnings Forecast

Next quarter’s earnings estimate for 26M is -€2.41 with a range of -€3.28 to -€1.99. The previous quarter’s EPS was -€2.29. 26M beat its EPS estimate 75.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 50.00% of the time in the same period. In the last calendar year 26M has Outperformed its overall industry.

26M Sales Forecast

Next quarter’s sales forecast for 26M is €20.97M with a range of €18.05M to €23.54M. The previous quarter’s sales results were €15.10M. 26M beat its sales estimates 50.00% of the time in past 12 months, while its overall industry beat sales estimates 62.69% of the time in the same period. In the last calendar year 26M has Underperformed its overall industry.

26M Stock Forecast FAQ

What is DE:26M’s average 12-month price target, according to analysts?

Based on analyst ratings, Mirati Therapeutics’s 12-month average price target is €53.94.

What is DE:26M’s upside potential, based on the analysts’ average price target?

Mirati Therapeutics has 1.19% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Mirati Therapeutics a Buy, Sell or Hold?

Mirati Therapeutics has a conensus rating of Hold, which is based on 0 buy ratings, 5 hold ratings and 0 sell ratings.

What is Mirati Therapeutics’s share price target?

The average share price target for Mirati Therapeutics is €53.94. This is based on 5 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is €54.24 ,and the lowest forecast is €53.32. The average share price target represents 1.19% Increase from the current price of €53.3.

What do analysts say about Mirati Therapeutics?

Mirati Therapeutics’s analyst rating consensus is a Hold. This is based on the ratings of 5 Wall Streets Analysts.

How can I buy shares of Mirati Therapeutics?

To buy shares of DE:26M, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Mirati Therapeutics (26M) Stock Forecast & Price Target

26M Analyst Ratings

26M Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Mirati Therapeutics

26M Analyst Recommendation Trends

26M Financial Forecast

26M Earnings Forecast

26M Sales Forecast

26M Stock Forecast FAQ

Get More with TipRanks Premium

Detailed List of Analyst Forecasts